

# SAFETY DATA SHEET

**Genentech**  
A Member of the Roche Group

## XOLAIR Vials 150 mg

Version  
1.0

Revision Date:  
06/14/2025

Date of last issue: -  
Date of first issue: 06/14/2025

### SECTION 1. IDENTIFICATION

Product name : XOLAIR Vials 150 mg  
Product code : RO548-9789/F01-01  
Common name(s),  
synonym(s) of the substance : XOLAIR Lyophilized Vials 150 mg

#### Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.  
Address : 1 DNA Way  
South San Francisco, CA 94080  
USA  
Telephone : 001-(650) 225-1000  
E-mail address : info.sds@roche.com  
Emergency telephone  
In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

#### Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

#### GHS label elements

Signal Word : Warning  
Hazard Statements : May form combustible dust concentrations in air.

#### Other hazards

None known.

---

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Omalizumab	242138-07-4	57.3
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	41.25
L-Histidine monohydrochloride monohydrate	5934-29-2	0.8

**XOLAIR Vials 150 mg**Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025

L-Histidine	71-00-1	0.5
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.15

---

**SECTION 4. FIRST AID MEASURES**

General advice : Do not leave the victim unattended.

If inhaled : If unconscious, place in recovery position and seek medical advice.  
If symptoms persist, call a physician.

In case of skin contact : Wash off with soap and water.

In case of eye contact : Remove contact lenses.  
Protect unharmed eye.  
If eye irritation persists, consult a specialist.

If swallowed : Keep respiratory tract clear.  
Do not give milk or alcoholic beverages.  
Never give anything by mouth to an unconscious person.  
If symptoms persist, call a physician.

Most important symptoms and effects, both acute and delayed : None known.

Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing

Notes to physician : Treat symptomatically.

---

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media : High volume water jet

Specific hazards during fire fighting : No information available.

Hazardous combustion products : Carbon monoxide  
Nitrogen oxides (NOx)  
Sulfur oxides

Further information : Standard procedure for chemical fires.  
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

**XOLAIR Vials 150 mg**Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Avoid dust formation.  
Refer to protective measures listed in sections 7 and 8.

Environmental precautions : If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Pick up and arrange disposal without creating dust.  
Sweep up and shovel.  
Keep in suitable, closed containers for disposal.

---

**SECTION 7. HANDLING AND STORAGE**

Advice on protection against fire and explosion : Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling : For personal protection see section 8.  
Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Materials to avoid : No materials to be especially mentioned.

Storage temperature : 2 °C to 8 °C  
Protect from heat and light  
Protect from moisture.

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: glass, Stainless steel

---

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Omalizumab	242138-07-4	IOEL	0.02 mg/m3	Roche Industrial

**XOLAIR Vials 150 mg**
Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025

				Hygiene Committee (RIHC)
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl	57-50-1	TWA	10 mg/m3	ACGIH
		TWA (Respirable)	5 mg/m3	NIOSH REL
		TWA (total)	10 mg/m3	NIOSH REL
		TWA (total dust)	15 mg/m3	OSHA Z-1
		TWA (respirable fraction)	5 mg/m3	OSHA Z-1
		TWA (Total dust)	15 mg/m3	OSHA P0
		TWA (respirable dust fraction)	5 mg/m3	OSHA P0

**Personal protective equipment**

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**

Material : Nitrile rubber  
Break through time : > 30 min  
Glove thickness : > 0.11 mm

Material : butyl-rubber  
Break through time : > 480 min  
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : General industrial hygiene practice.

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**


---

**XOLAIR Vials 150 mg**

Version 1.0 Revision Date: 06/14/2025 Date of last issue: -  
Date of first issue: 06/14/2025

Appearance : solid, (lyophilized)

Color : white

Odor : Not applicable

Odor Threshold : Not applicable

pH : Not applicable

Melting point/ range : No data available

Boiling point/boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Self-ignition : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : completely miscible

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : Not applicable

Viscosity, kinematic : Not applicable

**XOLAIR Vials 150 mg**Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025

Explosive properties : No data available

Oxidizing properties : No data available

Particle characteristics  
Particle Size Distribution : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Stable under recommended storage conditions.  
No hazards to be specially mentioned.

Conditions to avoid : No data available

No data available

Incompatible materials : No data available

Not applicable

Hazardous decomposition products : No data available

No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Not classified due to lack of data.

**Components:****Omalizumab:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : LD<sub>0</sub> (Monkey): 200 mg/kg  
Application Route: i.v.**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**Acute oral toxicity : LD<sub>50</sub> Oral (Rat): 29,700 mg/kg**Skin corrosion/irritation**

Not classified due to lack of data.

**Serious eye damage/eye irritation**

Not classified due to lack of data.

**XOLAIR Vials 150 mg**Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025**Respiratory or skin sensitization****Skin sensitization**

Not classified due to lack of data.

**Respiratory sensitization**

Not classified due to lack of data.

**Germ cell mutagenicity**

Not classified due to lack of data.

**Components:****Omalizumab:**

Genotoxicity in vitro : Test Type: Ames test  
Test system: *Salmonella typhimurium*  
Metabolic activation: with and without metabolic activation  
Result: negative

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

**Carcinogenicity**

Not classified due to lack of data.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Not classified due to lack of data.

**Components:****Omalizumab:**

Effects on fetal development : Species: cynomolgus monkey, female  
Application Route: s.c.  
General Toxicity Maternal: NOAEL: 75 mg/kg bw/day  
Embryo-fetal toxicity.: NOAEL: 75 mg/kg bw/day  
Result: No adverse effects.

**XOLAIR Vials 150 mg**Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025**STOT-single exposure**

Not classified due to lack of data.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**STOT-repeated exposure**

Not classified due to lack of data.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Repeated dose toxicity****Components:****Omalizumab:**

Species	:	cynomolgus monkey
LOEL	:	30 mg/kg/w
Application Route	:	s.c.
Exposure time	:	26 Weeks

**Aspiration toxicity**

Not classified due to lack of data.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

No data available

**Further information****Product:**

Remarks : No data available

**Components:****Omalizumab:**

Remarks : anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : Health injuries are not known or expected under normal use.

**XOLAIR Vials 150 mg**Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**Persistence and degradability****Components:****Omalizumab:**

Biodegradability : Result: Globular proteins are generally well biodegradable

**Bioaccumulative potential****Components:****Omalizumab:**

Partition coefficient: n-octanol/water : Remarks: No data available

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Partition coefficient: n-octanol/water : log Pow: -3.7 (68 °F / 20 °C)

**Mobility in soil**

No data available

**Other adverse effects****Product:**Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances  
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Additional ecological information : No data available

**XOLAIR Vials 150 mg**Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025**Components:****Omalizumab:**Additional ecological  
information

: Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable

**Domestic regulation****49 CFR**

Not regulated as a dangerous good

**Special precautions for user**

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

---

**SECTION 15. REGULATORY INFORMATION****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

Components	CAS-No.	Component TPQ (lbs)
<b>SARA 311/312 Hazards</b>	: Combustible dust	

## XOLAIR Vials 150 mg

Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025

### Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

### Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

### US State Regulations

#### Massachusetts Right To Know

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

#### Pennsylvania Right To Know

Omalizumab 242138-07-4

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

#### Maine Chemicals of High Concern

#### Vermont Chemicals of High Concern

#### Washington Chemicals of High Concern

#### California Permissible Exposure Limits for Chemical Contaminants

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

#### The ingredients of this product are reported in the following inventories:

AIIC : Not in compliance with the inventory

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Omalizumab

L-Histidine monohydrochloride monohydrate

NZIoC : On the inventory, or in compliance with the inventory

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory


**XOLAIR Vials 150 mg**Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025

TCSI	:	Not in compliance with the inventory
TSCA	:	Product contains substance(s) not listed on TSCA inventory.
TECI	:	Not in compliance with the inventory

**TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

**SECTION 16. OTHER INFORMATION****Further information****NFPA 704:****HMIS® IV:**

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA P0	:	USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values)
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA	:	8-hour time weighted average
OSHA Z-1 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response,

**XOLAIR Vials 150 mg**Version  
1.0Revision Date:  
06/14/2025Date of last issue: -  
Date of first issue: 06/14/2025

Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 06/14/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2404